TICKERNOMICS Sign up
Last Update: 2024-12-27 15:28:57
Akari Therapeutics Plc ( AKTX ) https://www.akaritx.com
0.98USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United Kingdom
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-67.33%
AKTX
SPY
32.66%
-96.71%
AKTX
SPY
108.59%
-97.15%
AKTX
SPY
302.52%
-99.90%
AKTX
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
11.83
9.58
0.09
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.61
115.95
-1.77
-98.49
0.00
-0.50
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.2208
-2469.96
-2469.95
1.06
Other Earnings and Cash Flow Stats:
Akari Therapeutics Plc ( AKTX ) Net Income TTM ($MM) is -19.52
Akari Therapeutics Plc ( AKTX ) Operating Income TTM ($MM) is -20.16
Akari Therapeutics Plc ( AKTX ) Owners' Earnings Annual ($MM) is 0.00
Akari Therapeutics Plc ( AKTX ) Current Price to Owners' Earnings ratio is 0.00
Akari Therapeutics Plc ( AKTX ) EBITDA TTM ($MM) is -20.14
Akari Therapeutics Plc ( AKTX ) EBITDA Margin is 0.00%
Capital Allocation:
Akari Therapeutics Plc ( AKTX ) has paid 0.00 dividends per share and bought back -6.797692 million shares in the past 12 months
Akari Therapeutics Plc ( AKTX ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Akari Therapeutics Plc ( AKTX ) Interest-bearing Debt ($MM) as of last quarter is 0
Akari Therapeutics Plc ( AKTX ) Annual Working Capital Investments ($MM) are -2
Akari Therapeutics Plc ( AKTX ) Book Value ($MM) as of last quarter is -7
Akari Therapeutics Plc ( AKTX ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Akari Therapeutics Plc ( AKTX ) has 2 million in cash on hand as of last quarter
Akari Therapeutics Plc ( AKTX ) has 9 million of liabilities due within 12 months, and long term debt 1 as of last quarter
Akari Therapeutics Plc ( AKTX ) has 12 common shares outstanding as of last quarter
Akari Therapeutics Plc ( AKTX ) has 0 million USD of preferred stock value
Academic Scores:
Akari Therapeutics Plc ( AKTX ) Altman Z-Score is -150.15 as of last quarter
Akari Therapeutics Plc ( AKTX ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Akari Therapeutics Plc ( AKTX ) largest shareholder is owning shares at 0.00 ($MM) value
Mark S Cohen(an insider) Bought 1055600 shares of Akari Therapeutics Plc ( AKTX ) for the amount of $200564.00 on 2015-09-18
11.91% of Akari Therapeutics Plc ( AKTX ) is held by insiders, and 0.51% is held by institutions
Akari Therapeutics Plc ( AKTX ) went public on 2015-09-21
Other Akari Therapeutics Plc ( AKTX ) financial metrics:
FCF:-10.47
Unlevered Free Cash Flow:0.00
EPS:-0.95
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:172.99
Beta:1.06
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Akari Therapeutics Plc ( AKTX ) :
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.